SCHEMBL4526922

SCHEMBL4526922

O=C1C(Cc2ccc(OCC(F)(F)F)cc2Cl)CCN1C1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.47
HPGD P15428 1/20 0.36
LIPE Q05469 6/20 0.36
PPARG P37231 2/20 0.36
PPARD Q03181 2/20 0.36
PPARA Q07869 2/20 0.36
CTSS P25774 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
FFAR1 O14842 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
PRCP P42785 1/20 0.34
PIM1 P11309 1/20 0.33
PDGFRA P16234 1/20 0.33
S1PR1 P21453 1/20 0.33
S1PR5 Q9H228 1/20 0.33
DRD2 P14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4520465 0.87 HPGD (0.48) HSD11B1HPGDFFAR1POLB
SCHEMBL4513450 0.86 HSD11B1 (0.48) HSD11B1HPGD
SCHEMBL4517793 0.86 HSD11B1 (0.52) HSD11B1ALDH1A1POLB
SCHEMBL4525800 0.85 HSD11B1 (0.47) HSD11B1HPGDFFAR1ALDH1A1POLB
SCHEMBL4519244 0.85 HSD11B1 (0.47) HSD11B1HPGDFFAR1ALDH1A1POLB
SCHEMBL4519067 0.85 HSD11B1 (0.50) HSD11B1PPARGSIGMAR1FFAR1
SCHEMBL13674511 0.85 HSD11B1 (0.47) HSD11B1HPGDFFAR1POLB
SCHEMBL4516252 0.84 HSD11B1 (0.55) HSD11B1HPGDFFAR1POLBS1PR1
SCHEMBL4523807 0.84 HSD11B1 (0.46) HSD11B1HPGDPPARGFFAR1
SCHEMBL4521181 0.84 HSD11B1 (0.46) HSD11B1HPGDFFAR1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HPGD 63/4885LIPE 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.